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Abstract
Aims There is no quality of life tool specifically developed for patients with severe aortic stenosis (AS) to assess how this
chronic condition and its treatment affect patients. The Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ) has been
developed to overcome this gap. The results of the validation of the TASQ in patients undergoing treatment for severe AS are
presented.
Methods and results Prospective study at 10 centres in Europe and Canada, which enrolled 274 patients with severe symp-
tomatic AS undergoing surgical or transcatheter aortic valve replacement. Mean TASQ score at baseline was 71.2 points and
increased to 88.9 three months after aortic valve implantation (P< 0.001). Increases were seen for the emotional impact (32.0
to 39.0; P < 0.001), physical limitations (14.8 to 22.0; P < 0.001), and physical symptoms (8.5 vs. 11.0; P < 0.001) domains.
Internal consistency was good/excellent for overall TASQ score (α = 0.891) and for the physical limitation, emotional impact,
and social limitation domains (α = 0.815–0.950). Test–retest reliability was excellent or strong for the overall TASQ (intraclass
correlation coefficient of 0.883) and for the physical symptoms, physical limitation, emotional impact, and social limitation do-
mains (intraclass correlation coefficient of 0.791–0.895). Responsiveness was medium overall (Cohen’s d = 0.637) and
medium/large for physical symptoms, emotional impact, and physical limitations (0.661–0.812). Sensitivity to change was sig-
nificant for physical symptoms, physical limitations (both P < 0.001), emotional impact (P = 0.003), and social limitations
(P = 0.038).
Conclusions The TASQ is a new, brief, self‐administered, and clinically relevant health‐specific tool to measure changes in
quality of life in patients with AS undergoing an intervention.
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Introduction
Chronic heart failure (HF) is characterized by congestion of
the lungs, shortness of breath, and a decline in physical ca-
pacity. Most causes of HF such as myocardial infarction are
irreversible, and treatment options include pharmacotherapy
and implantable supporting devices. HF may also be due to
aortic valve stenosis (AS), which is a common condition in
the elderly1 but tends to be asymptomatic for a very long
time. As soon as symptoms (e.g. angina, shortness of breath,
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and dizziness/syncope) develop, the prognosis is significantly
impaired, as is quality of life (QoL). The symptoms resemble
the clinical presentation of HF; however, AS is curable in prin-
ciple, and replacement of the stenosed valve reinstates the
non‐diseased state.
A gain in quality‐adjusted life years is the ultimate goal for
the treatment of both common HF and AS‐related HF. Spe-
cific questionnaires, such as the Kansas City Cardiomyopathy
Questionnaire (KCCQ), were developed as a health status
measure for patients with common forms of HF. Because of
the similarities with symptoms seen in AS‐related HF, the
KCCQ has also been used extensively in aortic valve (AV) re-
placement trials.2–4 However, the KCCQ is focused on
HF‐specific symptoms and may not capture symptoms that
are specific to severe AS as well5 where the left ventricular
function is often normal. It also fails to take into account fea-
tures relevant prior to and after undergoing an AV interven-
tion, such as surgical AV replacement (SAVR) or
transcatheter AV implantation (TAVI), and is unlikely to be
able to differentiate between outcomes after the various
procedures.
It is for these reasons that the Toronto Aortic Stenosis
Quality of Life Questionnaire (TASQ) was developed.5,6 This
questionnaire reflects AS‐specific symptoms and how they af-
fect a patient’s physical and mental well‐being, as well as
evaluating the patient’s assessment of their general health.
It is short, convenient to use and dedicated for patients with
AS. It has been shown to provide an accurate picture of QoL
in patients with severe AS before and after treatment.5,6
Here, we present the results of the validation of the TASQ
in patients undergoing treatment for severe AS, based on a
prospective, multinational registry.
Methods
The TASQ registry was a prospective observational registry
with a follow‐up period of 3 months.5,6 Patients with se-
vere symptomatic AS were recruited from 10 centres in
nine countries in Europe (Austria/Germany,2 France,2
Italy,2 Spain,2 and the UK1) and one centre in Canada with
the intention to have at least two sites for each language.
Patients either underwent transfemoral (TF) TAVI using the
balloon expandable SAPIEN 3 valve (Edwards Lifesciences)
or SAVR using any commercially available surgical valve.
The treatment decision was made by the heart team at
each centre, based on standard in‐house protocols, and
was independent of the study. Patients were excluded from
the study if they were unable to complete the question-
naire due to cognitive impairment. The study protocol
was approved by the independent ethics committee or in-
stitutional review board at each centre. The registry was
conducted in accordance with the Declaration of Helsinki
and its amendments, as well as country‐specific laws and
regulations. Patients were required to provide written in-
formed consent.
Toronto Aortic Stenosis Quality of Life
Questionnaire, Kansas City Cardiomyopathy
Questionnaire, and Short Form‐12 version 2
questionnaires
For the purpose of this registry, the TASQ was produced in
English (available open access5,6) and translated into French,
German, Italian, and Spanish. Validated translations were
performed in the target countries and supervised by an expe-
rience Clinical Outcomes specialist. Questionnaires were for-
ward translated twice and back translated once by qualified
translators, followed by a cognitive interview on five patients
with a heart condition. Questionnaires were then proofread
and released. For comparative purposes, patients were re-
quired to complete the TASQ, the KCCQ, and the Short
Form‐12 version 2 (SF‐12v2) at baseline prior to the interven-
tion, pre‐discharge, and at 30 days and 3 months of follow‐
up. The three questionnaires were given to the patient se-
quentially, but in a random order.
The scoring of the TASQ6 is based on a consistent 7‐point
scale for each of the 16 questions, covering response options
from ‘not very much’ to ‘very much’. The TASQ consists of
five domains: physical symptoms (Questions 1 and 14), phys-
ical limitations (Questions 3, 6, 7, and 15), emotional impact
(Questions 2 and 8 to 13), social limitations (Questions 4
and 5), and health expectations (Question 16). Each question
has a maximum score of 7, giving the complete questionnaire
a maximum total score of 112 with a higher score indicating
improved QoL. The full questionnaire is available at www.
tasq-q.com.
The KCCQ7 is a 23‐item self‐administered questionnaire
that addresses specific health domains: physical limitation,
symptoms, QoL, social limitation, symptom stability, and
self‐efficacy—the first four of which are combined into an
overall summary scale. Values for the domains range from 0
to 100, with higher scores indicating lower symptom burden
and better QoL. The self‐efficacy domain is designed to assess
whether or not patients feel they have the knowledge and
skills to manage their HF as an outpatient. The KCCQ has
been used in several AS‐related analyses.3,8,9
Generic health status was assessed with the SF‐12v2. The
SF‐12 is a reliable and valid measure of generic health status
that provides overall physical and mental component sum-
mary scores.10 Scores are standardized using norm‐based
methods to generate a mean of 50 and an SD of 10, with
higher scores indicating better health status.11 The maximum
score for both physical and mental component summary
scores is 100.
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Study objectives
The principal objective of the registry was to validate the
TASQ in patients with severe symptomatic AS undergoing
valve replacement.
Statistical analysis
The overall analytic approach is outlined in Supporting In-
formation, Table S1. The internal consistency of items in
the TASQ was measured using Cronbach’s alpha. Construct
validity was correlated with the KCCQ, the SF‐12v2 Physical
and Mental Component Scores, and the New York Heart
Association (NYHA) class as applicable. Floor effects were
calculated by comparing the number of patients scoring
the worst possible score on the TASQ to the number of
the patients scoring the worst possible score on the KCCQ.
Ceiling effects were calculated in the same manner. Re-
sponsiveness and sensitivity to change before and after
the AV procedures and at the follow‐up time points were
analysed with paired t‐tests. Furthermore, because of nor-
mally distributed values, t‐tests were used to compare
baseline to pre‐discharge, 30 days and 3 months of out-
comes, and to compare 30 days to 3 months in terms of
both QoL and patient expectations. Changes between pre‐
discharge, 30 days and 3 months of test results measured
responsiveness and sensitivity to change. Lastly, comparison
analyses of QoL among the three QoL tools (TASQ, KCCQ,
and SF‐12v2) were performed to identify interactions be-
tween procedural group and measurement tool. The overall
summary score was correlated to the NYHA class, the
KCCQ, and the SF‐12v2.
Results
Patient population
A total of 274 patients (137 undergoing TAVI and 137 un-
dergoing SAVR) were enrolled. Questionnaires were applied
in English (n = 64), French (n = 49), German (n = 49), Italian
(n = 64), and Spanish (n = 48). The average age of patients
was 77.6 years, most were male (62.8%), and the mean So-
ciety of Thoracic Surgeons risk score was 3.83 (Supporting
Information, Table S2). Most patients were independent,
with a mean Katz Index of 5.80 (max. score of 6.0) and
an Instrumental Activities of Daily Living score of 6.88
(max. score of 8.0). All patients had normal cognitive capa-
bilities (mean Mini Mental State Examination‐2 score of
26.2; max. score of 30).
Toronto Aortic Stenosis Quality of Life
Questionnaire, Kansas City Cardiomyopathy
Questionnaire, and Short Form‐12 version 2 over
3 months
There was a steady increase in the mean TASQ total score
from baseline (71.2) to 3 months of post‐treatment follow‐
up (88.9), with a mean difference of 17.7 points (Figure 1).
This increase was steady and statistically significant for the
emotional impact (39.0 vs. 32.0 points), physical limitations
(22.0 vs. 14.8 points), and physical symptoms (11.0 vs. 8.5
points) domains (each P < 0.001). On the other hand, the
score for social limitations dropped to 9.6 at discharge from
a baseline value of 10.2; it increased to 12.0 at 3 months.
Health expectations were essentially flat with a slight decline
from 5.8 to 4.8 at 3 months.
For the KCCQ, a similar increase in the total score was
observed (mean increase of 19.0 points for the overall sum-
mary score between baseline and Month 3, Figure 2), with
each domain being higher at 3 months than baseline. Phys-
ical limitation and social limitation were the only domains
for which an intermediate drop at the time of hospital dis-
charge was seen (from 65.0 to 56.7 and from 59.3 to 54.8,
respectively). The KCCQ does not have a health expecta-
tions domain, so comparison of this domain was not possi-
ble. Compared with the TASQ and the KCCQ, the
non‐specific SF‐12v2 was largely unchanged although signif-
icant between baseline and Month 3 (absolute difference
of 2.6 for the mental summary score and 5.8 for the phys-
ical summary score; Figure 3).
Reliability
Internal consistency for the TASQ was tested using
Cronbach’s alpha (Table 1). The overall TASQ score had good
consistency with an alpha of 0.891. This was also the case for
the physical limitations (0.815) and emotional impact (0.815)
domains, while social limitations had excellent consistency
(0.950). Consistency was poor for physical symptoms, with
an alpha of 0.579 (vs. threshold of 0.6).
Test–retest reliability vs. 1 and 3 months (Table 2) was ex-
cellent for the overall TASQ score (intraclass correlation coef-
ficient of 0.883) as well as for the physical symptoms (0.852),
physical limitations (0.826), and emotional impact (0.895) do-
mains. It was strong for social limitations (0.791) and moder-
ate for health expectations (0.524).
Responsiveness
Toronto Aortic Stenosis Quality of Life Questionnaire respon-
siveness was determined among patients who underwent AV
intervention and were alive at 1 month after the procedure
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(Table 3). Overall responsiveness was rated as medium
(Cohen’s d = 0.637). Among the domains, the effect size
was only rated as large for physical limitations (0.812), while
it was medium for physical symptoms (0.661) and emotional
impact (0.456), and small for both social limitations (0.208)
and health expectations (0.307).
The sensitivity to change after valve replacement (Table 4)
was significant for physical symptoms, physical limitations,
emotional impact, and social limitations but did not reach sta-
tistical significance for health expectations.
Validity
Construct validity was tested by correlating the TASQ and its
components to the NYHA class, the KCCQ, and the SF‐12v2
(Table 5). There was an adequate correlation (Pearson
>0.5) between the overall TASQ score and the KCCQ and
the SF‐12v2, and a negative correlation with the NYHA class
(0.367; P < 0.001). Correlations with the KCCQ and the
SF‐12v2 were generally strong for the TASQ domains of phys-
ical symptoms, physical limitations, emotional impact, and
Figure 1 Toronto Aortic Stenosis Quality of Life Questionnaire score before and at 30 days and 3 months after aortic valve replacement (surgical aortic
valve replacement or transcatheter aortic valve replacement)—total score (upper panel) and by domain (lower panel).
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social limitations, with the weakest correlations seen for
TASQ emotional impact (0.433) and social limitations (0.452)
with the SF‐12v2 physical component score. Correlations
were weak for the TASQ health expectations domain.
Discussion
The results of this study confirm that the TASQ is a reliable,
responsive, and valid measure of QoL in patients with severe
AS and is sensitive to change in patients undergoing AV
interventions.
Although various scales are available to evaluate QoL in
patients with cardiovascular disease, until now, there
has not been one that specifically assesses QoL in patients
with AS. In the past, the KCCQ has often been used in AS
studies because there are some similarities between
some of the symptoms of severe AS and those of HF due
to other causes. A level of validity for the KCCQ has
been established in trials of AV intervention.2–4 However,
the KCCQ focuses on HF‐specific symptoms and does
not capture parameters that are specific to AS.5 In
addition, the treatment of severe AS, and the likely out-
come of such treatment, differs from that for other types
of HF.
Figure 2 Kansas City Cardiomyopathy Questionnaire score before and at 30 days and 3 months after aortic valve replacement (surgical aortic valve
replacement or transcatheter aortic valve replacement)—total score (upper panel) and by domain (lower panel).
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Figure 3 Short Form‐12 version 2 score before and at 30 days and 3 months after aortic valve replacement (surgical aortic valve replacement or trans-
catheter aortic valve replacement)—total score (upper panel) and by domain (lower panel).
Table 1 Internal consistency of the TASQ
Domain Cronbach’s αa Degree of consistency
Physical symptoms (1, 14) 0.579 Poor consistency α < 0.6
Physical limitations (3, 6, 7, 15) 0.815 Good consistency 0.9 > α ≥ 0.8
Emotional impact (2, 8–13) 0.815 Good consistency 0.9 > α ≥ 0.8
Social limitations (4, 5) 0.950 Excellent consistency α ≥ 0.9
Health expectations (16) n.a.b n.a.b
TASQ total score 0.891c Good consistency 0.9 > α ≥ 0.8
n.a., not applicable; TASQ, Toronto Aortic Stenosis Quality of Life Questionnaire.
aCronbach’s α ≥ 0.9 indicates excellent consistency, 0.9 > α ≥ 0.8 is quite good, 0.8 > α ≥ 0.7 is acceptable, 0.7 > α ≥ 0.6 is questionable,
and α < 0.6 is poor.12
bWith only one item, no Cronbach’s α can be determined.
cCronbach’s α increases to 0.901 if Question 16 is not considered.
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Patients with severe AS develop symptoms of HF in the
presence of a preserved ejection fraction (HFpEF).
Long‐standing outflow obstruction leads to maladaptive con-
centric myocardial hypertrophy, which causes diastolic dys-
function independently of ejection fraction.13 Importantly,
this secondary form of HFpEF responds—at least in part—to
treatment of the underlying valvular disease.14 This contrasts
with primary HFpEF, which results from the interaction of
metabolic and haemodynamic risk factors (such as hyperten-
sion, obesity, diabetes mellitus, chronic kidney disease, and
atrial fibrillation) and does not have a specific underlying
cause.13 The cardinal symptoms of severe AS include angina
and syncope as well as symptoms of HF such as dyspnoea.15
A recent European registry study of patients with newly diag-
nosed severe AS found that 91% of symptomatic patients had
dyspnoea, 30% had dizziness on exertion/syncope, and 29%
had chest pain.1 In comparison, among patients with primary
HFpEF with structural heart disease (left ventricular hypertro-
phy or left atrial enlargement) enrolled in the large
PARAGON‐HF trial, the most common symptoms were dys-
pnoea on exertion (92%), oedema (38%), and angina
(29%).16 In the AS registry, the most common
co‐morbidities in patients with severe AS were severe renal
impairment (27%), atrial fibrillation (17%), and chronic lung
disease (13%).1 Among patients with primary HFpEF in
PARAGON‐HF, the most common co‐morbidities were hyper-
tension (95%), diabetes mellitus (43%), and atrial fibrillation
(32%).16 Treatment of symptomatic severe AS with AV inter-
vention reduces morbidity and mortality.15
Thus, although there are some similarities between HF as-
sociated with AS and HF due to some other causes, there are
also differences. The KCCQ was not designed to evaluate
symptoms specific to AS, or the changes in QoL resulting from
AV intervention. It would therefore be helpful to have a mea-
surement tool that can assess the effects of AS‐specific
symptoms/factors, and of AV intervention, on QoL. The TASQ
has been designed to address that need, by taking into ac-
count the physical, emotional, and social factors associated
with severe AS.5 It also includes a health expectations do-
main, which reflects how hopeful the patient is that their
health will improve, a factor that is not assessed by the KCCQ.
Some research identifies that patient expectations and per-
ceptions may impact post‐procedural outcomes including
QoL.17 Preliminary evaluation of the TASQ produced promis-
ing results.5 The current study has validated the TASQ in a
larger cohort of patients undergoing AV intervention.
The mean TASQ score increased (improved) steadily from
baseline to 3 months of post‐treatment follow‐up. The in-
crease was most pronounced for the emotional impact, phys-
ical limitations, and physical symptoms domains. A similar
Table 2 TASQ test–retest reliability
Domain 1 month mean 3 months mean Mean difference P‐value ICCa Agreement
Physical symptoms (1, 14) 11.0 11.3 0.31 0.039 0.852 Excellent
Physical limitations (3, 6, 7, 15) 21.4 22.5 1.14 0.003 0.826 Excellent
Emotional impact (2, 8–13) 38.3 39.9 1.59 0.009 0.895 Excellent
Social limitations (4, 5) 11.4 12.2 0.82 0.001 0.791 Strong
Health expectations (16) 4.9 4.5 0.43 0.054 0.524 Moderate
TASQ total score 87.0 90.4 3.43 0.002 0.883 Excellent
ICC, intraclass correlation coefficient; TASQ, Toronto Aortic Stenosis Quality of Life Questionnaire.
No patients with surgical aortic valve replacement were considered for this analysis as recovery is prolonged vs. transcatheter aortic valve
implantation. No patients were hospitalized between Months 1 and 3, and no patients had a change in New York Heart Association class.
aThe ICC (ratio of between‐groups variance:total variance) ranges from 0 to 1, with higher scores indicating increased test–retest reliabil-
ity. In general, an intraclass correlation coefficient of 0 to 0.2 indicates poor agreement, 0.3 to 0.4 fair agreement, 0.5 to 0.6 moderate
agreement, 0.7 to 0.8 strong agreement, and >0.8 excellent agreement.
Table 3 Determining TASQ responsiveness to clinical change
Domain Baseline meana 1 month meana Mean difference P‐value Effect size (Cohen’s d)
Physical symptoms (1, 14) 8.53 ± 2.64 10.53 ± 2.06 2.00 <0.001 0.661 Medium
Physical limitations (3, 6, 7, 15) 14.82 ± 5.93 20.37 ± 5.07 5.55 <0.001 0.812 Large
Emotional impact (2, 8–13) 32.03 ± 10.30 36.86 ± 9.37 4.83 <0.001 0.456 Medium
Social limitations (4, 5) 10.17 ± 3.98 11.08 ± 3.32 0.91 0.001 0.208 Small
Health expectations (16) 5.78 ± 1.42 5.26 ± 1.71 0.52 <0.001 0.307 Small
TASQ total score 71.09 ± 19.43 84.15 ± 17.33 13.06 <0.001 0.637 Medium
TASQ, Toronto Aortic Stenosis Quality of Life Questionnaire.
The responsiveness of the TASQ domains to a clinical change was first assessed among patients who underwent aortic valve replacement
and were alive at 1 month after the procedure (n = 243). Scores at baseline and 1 month were compared using paired t‐tests. Cohen’s d
effect size, which quantifies the magnitude of change relative to baseline variation, was also used to assess the responsiveness of the
questionnaire to clinical change. In general, an effect size of 0.2 to 0.3 indicates a small effect, around 0.5 is a medium effect, and
≥0.8 is a large effect.
aMean ± standard deviation.
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increase in the KCCQ total score was seen between baseline
and 3 months. In contrast, the SF‐12v2, a non‐specific QoL
questionnaire, did not change substantially between baseline
and 3 months.
Internal consistency was good or excellent (Cronbach’s
α > 0.8) for the overall TASQ score and for the physical limi-
tations, emotional impact, and social limitations domains.
This is generally consistent with the findings of a study
assessing the validity of the KCCQ in patients with severe
AS, in which good/excellent internal consistency was seen
for the KCCQ overall summary score and the physical limita-
tion, symptoms, and social limitation domains, with accept-
able consistency (α = 0.72) for the QoL domain.3 In the
current study, test–retest reliability was excellent or strong
for the overall TASQ score and for the physical symptoms,
physical limitations, emotional impact, and social limitations
domains and was moderate for health expectations, further
supporting the reliability of the TASQ.
In terms of the responsiveness of the TASQ to clinical
change (1 month post‐treatment vs. baseline), a medium ef-
fect size was seen for the overall TASQ score and for the
physical symptoms and emotional impact domains, with a
large effect size for the physical limitations domain. Only
small effects were seen for the social limitations and health
expectations domains. In the KCCQ validation study in AS, a
large responsiveness effect size was seen for overall sum-
mary, QoL, and symptoms domains and a moderate effect
size for physical limitations and social limitations.3 In the eval-
uation of sensitivity to change (as indicated by the relation-
ship between change in NYHA class and change in domain
score), the TASQ overall score and physical symptoms, phys-
ical limitations, emotional impact, and social limitations do-
mains showed excellent discriminatory ability. This is
consistent with the results reported previously for KCCQ do-
mains in patients with severe AS.3
In the evaluation of construct validity, a correlation (Pear-
son>0.5) was seen between the overall TASQ score and both
the KCCQ and the SF‐12v2. Strong correlations with the KCCQ
were seen for the TASQ domains of physical symptoms, phys-
ical limitations, emotional impact, and social limitations. Cor-
relations with the SF‐12v2 were strong for the TASQ domains
of physical symptoms, physical limitations, emotional impact,
















Physical symptoms (1, 14) 2.00 3.33 2.49 2.71 0.89 0.00 <0.001
Physical limitations (3, 6, 7,
15)
5.55 7.33 7.01 7.00 3.10 1.09 <0.001
Emotional impact (2, 8–13) 4.83 9.67 8.18 5.79 2.27 1.73 0.003
Social limitations (4, 5) 0.91 0.33 2.00 1.23 0.07 0.82 0.038
Health expectations (16) 0.52 0.0 0.21 0.67 0.35 1.18 0.374
TASQ total score 13.06 20.67 19.42 16.31 6.24 2.64 <0.001
NYHA, New York Heart Association; TASQ, Toronto Aortic Stenosis Quality of Life Questionnaire.
To examine the sensitivity of the TASQ to clinically relevant changes and its ability to discriminate between different levels of change, we
calculated the change in domain scores for all patients from baseline to 1 month stratified by their change in NYHA class during the same
period and examined the relation between the change in domain scores vs. the change in NYHA class using a linear trend test.
aANOVA.
Table 5 Construct validity: testing correlations (Pearson) of TASQ domains with other measures at 3 months
TASQ
Domain Physical symptomsPhysical limitationsEmotional impactSocial limitationsHealth expectationsTotal TASQ score
NYHA class 0.399 0.412 0.192 0.225 0.042 0.367
KCCQ
Total symptom score 0.708 0.730 0.524 0.597 0.090 0.686
Overall summary score 0.741 0.792 0.669 0.736 0.035 0.803
Clinical summary score 0.707 0.732 0.574 0.627 0.046 0.713
Social limitation n.a. n.a. n.a. 0.603 n.a. n.a.
QoL n.a. n.a. 0.714 0.708 0.046 0.801
SF‐12v2
Physical component score 0.587 0.611 0.433 0.452 0.007 0.555
Mental component score 0.574 0.561 0.628 0.597 0.113 0.680
Social functioning n.a. n.a. n.a. 0.660 n.a. n.a.
Role ‐ emotional n.a. n.a. 0.582 n.a. 0.161 n.a.
KCCQ, Kansas City Cardiomyopathy Questionnaire; NYHA, New York Heart Association; QoL, quality of life; SF‐12v2, Short Form‐12 version
2; TASQ, Toronto Aortic Stenosis Quality of Life Questionnaire.
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and social limitations (except for the latter two domains and
the SF‐12v2 physical component score). A negative correla-
tion was seen between the TASQ overall score and NYHA
class, with similar correlations seen for the physical symp-
toms, physical limitations, emotional impact, and social limi-
tations domains. Only weak correlations were seen between
the TASQ health expectations domain and the KCCQ, SF‐
12v2, or NYHA class.
Quality of life is an important consideration for patients
with severe AS, who are often elderly and have multiple
co‐morbid conditions.18–21 The KCCQ has been shown to be
valid and relevant in patients with severe AS,2–4 but it focuses
specifically on symptoms of HF and does not take into ac-
count factors that are specific to AS and its treatment. The
SF‐12v2 evaluates general health‐related QoL11 and is not
able to differentiate between the effects of AS and the ef-
fects of other conditions, which is important, given that pa-
tients with AS tend to have multiple co‐morbidities. The
TASQ incorporates parameters based on insight provided by
patients with severe AS, including symptoms, emotional and
social factors, and the implications of AS and its treatment
on the patient’s future.5 It also includes questions about
changes in symptoms over the previous 2 months, facilitating
the assessment of how valve replacement has affected QoL.
This instrument will enable more accurate evaluation of the
QoL of patients with severe AS, including the response to
treatment, and may facilitate appropriate treatment
decisions.
Limitations
The sample size used non‐probability sampling; recruitment
was aimed at facilitating equal distribution of patient num-
bers across languages. Patients were asked to complete three
different questionnaires at each time point, which may have
added to patient burden and may have been inconvenient
for some patients, potentially leading to poor compliance
and missing responses. In order to spread the risk of this
across all three forms, the questionnaires were administered
to patients in a random order. Patients were also evaluated
to ensure that they had adequate capability for completing
the forms and complying with study procedures. As such, pa-
tients with cognitive impairment were excluded from the
study. Finally, the TAVI subgroup included only those under-
going TF‐TAVI. This is because TF access was the standard
procedure used at participating centres.
Conclusions
The TASQ is a new, brief, self‐administered, and appropriate
health‐specific tool to measure changes in QoL in patients
with AS. Use of the TASQ may help to adequately assess
health outcomes in patients undergoing AV intervention.
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